Publication
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
Authors not recorded
Blood2015PMID 26486786stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerEssential Thrombocythemiacivic_curation1.00
- drugPeginterferon Alfa-2acivic_curation1.00
- geneCALRcivic_curation1.00
- variantCALR EXON 9 FRAMESHIFTcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26486786
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CALR EXON 9 FRAMESHIFT1 | ||||||||
| Peginterferon Alfa-2a | Essential Thrombocythemia | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1482Study explored the hematologic and molecular responses in a cohort of 31 patients presenting with thrombocythemia and CALR exon 9 frameshift mutations. All 31 patients exhibited a hematologic response… (full text at CIViC) PMID 26486786 · Verger et al., 2015 · Open in CIViC | civic |